

October 23,2024

The Secretary Listing Department, BSE Limited, 1 st Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400001 Scrip Code: 540975	The Manager, Listing Department, The National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ASTERDM
---	--

Dear Sir/Madam,

Sub: Press Release on unaudited financial results for the quarter and half year ended September 30, 2024

With reference to the captioned subject, please find enclosed press release in relation to the unaudited financial results of the Company for the quarter and half year ended September 30, 2024.

Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thank you

For Aster DM Healthcare Limited

Hemish Purushottam
Company Secretary and Compliance Officer
M. No: A24331

Aster DM Healthcare Q2 and H1 FY25 Results:

Aster India reports strong revenue and EBITDA performance.

**H1 FY25 revenues up 18% YoY to INR 2,088 Crs;
H1 FY25 Operating EBITDA up 44% YoY to INR 410 Crs**

Q2 FY25 revenues up 16% YoY to Rs. 1,086 Crs.; Op. EBITDA grew 48% to Rs. 233 Crs

Bengaluru, October 23, 2024: Aster DM Healthcare, one of the leading integrated healthcare service providers in India, today announced its financial results for the quarter ended September 30, 2024.

Key Financial Highlights

Revenue

- Revenue grew 18% YoY to INR 2,088 Crs. in H1 FY25 Vs. INR 1,772 Crs. in H1 FY24.
- Revenue grew 16% YoY to INR 1,086 Crs. in Q2 FY25 Vs. INR 934 Crs. in Q2 FY24.

EBITDA

- Operating EBITDA grew 44% YoY to INR 410 Crs. in H1 FY25 Vs. INR 285 Crs. in H1 FY24.
- Operating Margins stood at 19.6% in H1 FY25 as compared to 16.1% in H1 FY24.
- Operating EBITDA grew 48% YoY to INR 233 Crs. in Q2 FY25 Vs. INR 157 Crs. in Q2 FY24.
- Operating EBITDA Margins stood at 21.4% in Q2 FY25 Vs. 16.8% in Q2 FY24.

Profits

- PBT grew by 134% YoY to INR 284 Crs. in H1 FY25 Vs. INR 121 Crs. in H1 FY24.
- Net Profit (post NCI) grew by 88% to INR 171 Crs. in H1 FY25 Vs. INR 91 Crs. in H1 FY24.

Commenting on the performance for H1 FY25, Dr. Azad Moopen, Founder and Chairman, Aster DM Healthcare, said: *"We are pleased with the momentum built in the second quarter of FY25, which reflects our unwavering focus on operational excellence and capacity enhancement. In H1 FY25, our India business achieved 18% YoY growth, reaching INR 2,088 crores, driven by increased occupancy and growth in ARPOB. The Operating EBITDA grew by 44% YoY to INR 410 crores and net profits (post NCI) grew by 88% YoY to INR 171 crores in H1 FY25. The steady growth across our core businesses, combined with strategic cost optimization, has significantly strengthened our margins with H1FY25 Operating EBITDA margins standing at 19.6%."*

Dr. Moopen further added, "As we expand, with plans to surpass ~6,800 beds by FY27, Aster DM Healthcare is well-positioned to meet the increasing demand for advanced healthcare in India. I am pleased to share that 9 Aster Hospitals are now accredited in the new Digital Standards Published by NABH signifying our commitment to Digital Transformation. Amongst them 5 Hospitals have been accorded highest accreditation in Platinum category thus underscoring our leadership in digital healthcare transformation."

India Performance Highlights

- Overall Operating EBITDA margin of 19.6% in H1 FY25 (16.1% in H1 FY24)
- Core hospital business delivered Operating EBITDA margin of 22.4% in H1 FY25 (19.1% in H1 FY24)
- Matured hospital (6+ years since commencement) Op. EBITDA margins at 25% in H1 FY25 (22% in H1 FY24) and ROCE at 32%
- Aster Whitefield hospital (Bangalore) achieved ~67% occupancy levels and ARPOB at INR ~70,000 in H1 FY25
- ALOS has improved to 3.2 days in H1 FY25 from 3.4 days in H1 FY24
- Payor mix improved with Insurance business at 30% (i.e. +300 bps), offset by lower scheme business in H1 FY25.
- Aster Labs revenue grew by 17% YoY in Q2 FY25, continuing to deliver positive EBITDA margin at 11% in Q2 FY25 from 3.4% in Q1 FY25
- Successful operationalised 100 beds at MIMS Kannur in the last quarter.
- Plans to add ~1800+ beds by FY27; New addition of Aster Women and Child in Hyderabad with 300 beds

About Aster DM Healthcare, India

Aster DM Healthcare Limited is one of the largest healthcare service providers operating in India with a strong presence across primary, secondary, tertiary, and quaternary healthcare through 19 hospitals with 4,994 beds, 13 clinics, 212 pharmacies (Operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster), and 232 labs and patient experience centers across 5 states in India, delivering a simple yet strong promise to different stakeholders: “We’ll Treat You Well.” We are among the first 100 early adopters of these digital standards, showcasing our commitment to leveraging technology for enhanced healthcare delivery.

For more information about us, please visit www.asterdmhealthcare.com or contact:

Get in touch: Aster DM Healthcare	
Corporate Communications	Investor Relations
Sreehari Nair Email: sreehari.nair@asterdmhealthcare.in Mob: +91 9819288911	Puneet Maheshwari Email: puneet.maheshwari@asterdmhealthcare.in Mob: + 91 9920486380
	Himani Singla Email: himani.singla@asterdmhealthcare.in Mob: +91 9569926021

DISCLAIMER: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Aster DM Healthcare will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.